North West | Technology & innovation

Alcor-Bio's allergens get European quality mark

22 Mar '12
Allergens, made by St. Petersburg pharmaceutical company Alcor Bio, were marked with a CE-Mark, confirming that the products quality meets European Union safety requirements, RusNanoNet reports.

The marked group of medicines included eight newest allergens, produced in early March.

Today Alcor Bio produces 88 liquid biotinylated allergens. Under plans, a few dozen new kinds of allergens will be developed and produced in 2012.

Alcor Bio makes food, epidermal, mite, dust, mold, grass pollen, and mixture allergens. All the company’s products have been registered with the Federal Service of Surveillance in Healthcare and Social Development (Roszdravnadzor).

Out of the company’s 60 + products, 34 have the CE-mark.

The assessment of Alcor Bio’s medicines’ compliance with European quality requirements was performed by the company MediMarkt Europe.

Alcor Bio develops and produces test-systems of immune-ferment and molecular-genetic analysis.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
COMMENT ON THIS STORY
Find Related Content

Locations: St. Petersburg

Latest News: North West
24 Apr '19 | Technology & innovation | Finance, business
18 Mar '19 | Technology & innovation
22 Oct '18 | Finance, business | Technology & innovation
9 Oct '18 | Finance, business
 

Feature stories

4 Apr '19
Russian scientists have come up with what they say is...
29 Jan '19
Russian biologists and biophysicists have developed...
2 Nov '18
Drawing upon in-depth interviews, the book channels...
Search (News archive - 21349)
Advertising
Venture_Russia_2018
Advertising
NATT
Advertising
StartUp-Village
Advertising
Independent Software Developers Forum
Advertising
Marchmont News

Latest News

22 May '19
Russia teams up with a private equity firm from...
20 May '19
An intelligent cardiovascular diseases diagnostics...
17 May '19
MTS, one of Russia’s main mobile operators, has...

Most read stories from last week

20 May '19
An intelligent cardiovascular diseases diagnostics...
22 May '19
Russia teams up with a private equity firm from...